Table 2.

Statin use in TEMPO 3:4 and REPRISE

VariableTEMPO 3:4REPRISE
TolvaptanPlaceboTolvaptanPlacebo
Use of statins, n12964203201
Percentage of randomized subjects13133029
Duration of statin use, d
 Mean746779313328
 Median10651049359358
 SD42739210279
 10th percentile, 90th percentile27, 110224, 1097101, 365188, 364
 Minimum, maximum1, 11201, 11101, 38714, 383
Statin permanent discontinuations, n (%)48 (37)27 (42)14 (7)14 (7)
Decreased statin dose, n (%)9 (7)4 (6)4 (2)4 (2)
Increased statin dose, n (%)12 (9)2 (3)5 (2)2 (1)
Changed statin, n (%)16 (12)10 (16)10 (5)6 (3)
  • TEMPO 3:4, Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 trial; REPRISE, Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD trial.